Should menopausal women at increased risk for breast cancer use tamoxifen, raloxifene, or hormone therapy?: A framework for personalized risk assessment and counseling

Journal of Cancer Education

Volumn 22, Issue 1, 2007, Pages 10-14

  Matloff, Ellen T ^a   Shannon, Kristen M ^b   Moyer, Anne ^c   Col, Nananda F ^d  

^a YALE CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; RALOXIFENE; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CASE REPORT; DEPRESSION; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC COUNSELING; HODGKIN DISEASE; HUMAN; MENOPAUSE; ONCOGENE; OSTEOPOROSIS; PATIENT COUNSELING; PATIENT DECISION MAKING; PATIENT EDUCATION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR;

EID: 34547190162     PISSN: 08858195     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03174368     Document Type: Article

References (34)

1. Daly M, Lerman C, Ross E, et al. Gail model breast cancer risk components are poor predictors of risk perception and screening behavior. Breast Cancer Res Treat. 1996;41:59-70.
2. Claus E, Schildkraut J, Thompson W, et al. The genetic attributable risks of breast and ovarian cancer. Cancer. 1996;77:2318-2324.
3. Couch F, DeShano M, Blackwood M, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. New Engl J Med. 1997;336:1409-1415.
4. Hartmann L, Schaid D, Woods J. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. New Engl J Med. 1999;340:77-84.
5. Kerlikowske K. Performance of screening mammography among women with and without a first degree relative with breast cancer. Ann Intern Med. 2000;133:855-863.
6. Chlebowski R, Collyar D, Somerfield M. American Society of Clinical Oncology technology assessment of breast cancer risk reduction strategies: Tamoxifen and raloxifene. J Clin Oncol. 1999;17:1939-1955.
7. Fisher B, Constantino J, Wickerman D. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
8. Bergman L. Risk and prognosis of endometrial cancer after Tamoxifen for breast cancer. Lancet. 2000;356:881-887.
9. Decensi A. Effect of Tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation. 2005;111:650-656.
10. Morales L. Acute effects of Tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs 2004;15:753-760.
11. Vogel V, Constantino J, Wickerman D, et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes; the NSABP study of tamoxifen and raloxifene (STAR) P-2 Trial. JAMA. 2006;295(23).
12. Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol. 2005;23:1636-1643.
13. Morrissey D, Kirchner J. Management of the climacteric. Options abound to relieve women's midlife symptoms. Postgrad Med. 2000;108:85-100.
14. Women's Health Initiative (WH1). Risks and benefits of estrogen plus progestin in healthy postmenopausal women, principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA. 2002;288:321-333.
15. Haas J, Kaplan C, Gerstenberger E, et al. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med. 2004;140:184-188.
16. Matloff E. Genetic counseling. In: DeVita V, Hellman S, Rosenberg S (eds.). Cancer: Principles and Practice of Oncology. 7th Ed. Philadelphia: Lippincott-Raven; 2005.
17. Schoelle S, Chang J, Harman J, et al. Trends in women's health services by type of physician seen: data from the 1985 and 1997-98 NAMCS. Womens Health Issues. 2002;12:165-177.
18. Theroux R, Taylor K. Women's decision making about the use of hormonal and nonhormonal remedies for the menopausal transition. J Obstet Gynecol Neonatal Nurs. 2003;32:712-723.
19. Burg M, Fraser K, Gui S, et al. Treatment of menopausal symptoms in family medicine settings following the Women's Health Initiative findings. J Am Board Fam Med. 2006;19:122-131.
20. Matloff E, Moyer A, Shannon K, et al. Healthy women with a family history of breast cancer: Impact of a tailored genetic counseling intervention on risk perception, knowledge, and menopausal therapy decision-making. J Womens Health. 2006; 15(7):843-856.
21. Santen R, Borwhat M, Gleason S. Menopause: What Every Woman Should Know. The Endocrine Society; 1997.
22. Col N, Eckman M, Karas R, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA. 1997;277:1140-1147.
23. Col N, Pauker S, Goldberg R, et al. Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women. Arch Intern Med. 1999;159:1458-1466.
24. Col N, Weber G, Stiggelbout A, et al. Short-term menopausal hormone therapy for symptom relief: an updated decision model. Arch Intern Med. 2004;164:1634-1640.
25. Epstein R, Alper B, Quill T. Communicating evidence for participatory decision making. JAMA. 2004;291:2359-2366.
26. Sampson H. Alcohol and other factors affecting osteoporosis risk in women. Alcohol Res Health. 2002;26:292-298.
27. Clamp A, Danson S, Clemons M. Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies. Lancet Oncol. 2002,3:611-619.
28. Travis L, Hill D, Dores G. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003;290:465-475.
29. Women's Health Initiative (WHI). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
30. American College of Physicians (ACP). Guidelines for counseling postmenopausal women about preventative hormone therapy. Ann Intern Med. 1999;117:1038-1041.
31. Connelly M, Ferrari N, Hagen N. Patient-identified needs for hormone replacement therapy counseling: A qualitative study. Ann Intern Med. 1999;131:265-268.
32. Greendale K, Pyeritz R. Empowering primary care health professionals in medical genetics: how soon? how fast? how far? Am J Med Genet. 2001;106:223-232.
33. Fry A, Campbell H, Gudmundsdottir H, et al. GP's views on their role in cancer genetics services and current practice. Fam Pract. 1999;16:468-474.
34. Wilkins-Haug L, Erickson K, Hill L, et al. Obstetrician-Gynecologist's opinions and attitudes on the role of genetics in women's health. J Women Health Gen-B. 2000;9(8).